A Phase 4 interventional study of Neostigmine and Sugammadex in Neuromuscular Blockade, Sugammadex and Neostigmine, sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital. Completed. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-10-04.
Sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing sugammadex in Delayed Emergence from Anesthesia — 2 open to participants now, 2 under way, none of them phase 3. Sugammadex · Delayed Emergence from Anesthesia.
Among the 14 studies testing sugammadex in Delayed Emergence from Anesthesia, this one is the 5th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 4, and was the 9th registered.
98 studies on the registry are indexed under Delayed Emergence from Anesthesia; 17 are open to participants now.
Browse Delayed Emergence from Anesthesia studies →2 of the 14 studies testing sugammadex in Delayed Emergence from Anesthesia are open now, in 2 countries. Recruiting first, the newest first:
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18–80
University Hospital, Caen · Sites in France
Ages 1 mo–24 mo
By country, each count listing its studies:
Sugammadex: first FDA approval 2015 (BRIDION), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 8 Delayed Emergence from Anesthesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 40 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 113 is above the median of 83 across 58 interventional studies indexed under Delayed Emergence from Anesthesia.
Median enrollment 92 across the 14 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital is the lead sponsor of 22 studies on the registry; 3 are open to participants now.
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital has 1 study filed under Delayed Emergence from Anesthesia — fewer than ten, so there is no comparison to draw.
1 of the studies testing sugammadex in Delayed Emergence from Anesthesia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477132University Hospital, CaenA Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing sugammadex in Delayed Emergence from Anesthesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Sugammadex may prevent residual neuromuscular blockade by providing rapid reversal at the end of the operation. Our goal is to compare the half-dose use of sugammadex for reversing residual blockade after administration of neostigmine and atropine to the routine use of reversal medication.
Background: Postoperative residual neuromuscular block (PONB) may be observed in patients in the recovery room after surgery, and this event causes significant adverse events such as respiratory muscle weakness, decreased tidal volumes causing hypoxemia, reintubation, prolonged mechanical ventilation, and possible risk for a cardiopulmonary arrest.
Goal: The study investigators hypothesized to investigate the effects of the half-dose use of sugammadex for reversing residual blockade after administration of neostigmine and atropine and compare these results to the routine full-dose use neostigmine and atropine.
The Study Design:
The study investigators planned to perform a prospective, single-blinded, randomized trial.
The study Protocol:
The investigators enrolled patients undergoing lower abdominal tumor resection surgery under general anesthesia who fulfill our inclusion criteria.
The study is single-blinded because the anesthesia resident, anesthesia technician, and anesthesia personnel, including the data collector, were blinded to the randomization. The supervising anesthesiologist was also a data collector, and she was not blinded to the study protocol.
The randomization into two groups required the use of a computer system. The study investigators performed a random allocation sequence by the use of randomized block design codes that are generated from a computer. Afterward, the study investigators opened an opaque and sealed envelope that contained the generated codes and randomly divided patients into two groups. During this process, they made sure that all study personnel was blinded to the randomization.
The study investigators divide patients into two groups after the randomization process, and the groups are as follows: The first group of 48 patients is called Group N. In this group of patients, and we administer intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg in a single syringe before extubation. The second group of 50 patients is called Group N+S. In Group N+S, the study investigators administered the standard reversal medications of intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. Three minutes later, the study 'investigators administered an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent.
The Study Measurement of Parameters. The patients require general anesthesia induction with an intermediate-acting neuromuscular blocking age, rocuronium, at a dose of 0.06 mg/kg intravenously.
After induction of anesthesia and before administration of rocuronium, the investigators monitored train-of-four (TOF) counts using a monitoring device of neuromuscular blockade at the patient's ulnar nerve. For this purpose, they placed two surface electrodes above the ulnar nerve near the wrist. To monitor the nerve stimuli at the adductor pollicis muscle using acceleromyography (TOF Watch SX, Schering-Plough Ireland, Dublin, Ireland). After induction of general anesthesia, the TOF Watch device provided 50-Hz tetanic stimulation for 5 seconds, and one minute after this tetanic stimulation, it offered a train-of-four (TOF) stimulation. Depending on the TOF-watch-related parameters, they decided to administer rocuronium, the neuromuscular agent, or not. At the end of the surgery, all anesthetics needed to be discontinued, including inhalational agents who were sevoflurane and nitrous oxide. Once the end-tidal concentration of sevoflurane reached a 0.4-0.6% level, the investigators administered the previously randomized reversal study drug.
For the administration of the reversal agents, there was a need for a TOF count of 2 observed in the TOF Watch device. A TOF count of 2 in TOF Watch monitoring provided information of a shallow neuromuscular block.
The Collected Parameters. They observed the clinical signs of recovery using several parameters. These parameters are level of consciousness, head-lift test, ability to sustain head lift, general muscle weakness, laryngospasm, and desaturation.
The study investigators collected the periods between the last dose of intravenous rocuronium and administering a reversal agent, administering a reversal agent to extubation, and administering a reversal agent to operating room discharge. These periods were in minutes. They also collected the recovery periods between the start of helping reversal agent to the recovery of TOF ratio \< 0.9 to 0.7 and TOF ratio ≥ 0.9, which were in minutes.
They collected hemodynamical data, including; noninvasive mean arterial pressure, heart rate measurements, and peripheral oxygen saturation values before and subsequently at 2, 5, 10, and 30 minutes after administering the reversal drugs and in the recovery room.
The primary outcome was the incidence of a train-of-four (TOF) ratio less than 0.9 at tracheal extubation. The secondary outcomes were periods between the start of administering reversal agents and extubation or operating room discharge in minutes to achieve recovery of TOF ratio \< 0.9 to 0.7 and TOF ratio ≥ 0.9.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Group N (Neostigmine) (n=48), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation. A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio \< 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes.
Drug: Neostigmine
In Group N+S (Neostigmine+Sugammadex) (n=50), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation. After a three-minute waiting period, the study investigators administered an intravenous bolus half-dose of 1 mg/kg of sugammadex after the standard reversal dose. A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio \< 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes.
Drug: Sugammadex
The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation. In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge.
Also known as: Routine full-dose reversal medication
The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to \>0.9 in the recovery room before discharge to the ward.
Also known as: Routine full-dose reversal medication and half-dose sugammadex
Incidence of postoperative residual neuromuscular blockade (rNMB)
Incidence of postoperative residual neuromuscular blockade (rNMB) (defined as a train-of-four ratio, TOFR \<0.9) measured 15 min after administration of the reversal agent.
Time frame: After operation within 24 hours
Recovery time-1
The comparison of the recovery periods between groups when the start of administering reversal agent to the recovery of TOF ratio \< 0.9 to 0.7
Time frame: After operation within 120 minutes
Recovery time-2
The comparison of the recovery periods between groups when the start of administering reversal agent to the recovery of TOF ratio \< 0.7
Time frame: After operation within 120 minutes
Recovery time-3
The comparison of the recovery periods between groups when the start of administering reversal agent to the recovery of TOF ratio≥ 0.9
Time frame: After operation within 24 hours
Muscle strength after extubation
The clinical assessment of muscle strength in the operating room are as follows; awake status, The investigated parameters were; arousable with minimal stimulation, cooperativeness, responsive only to tactile stimulation, cooperativeness, and able to perform five-second head lift.
Time frame: After operation within 24 hours
Adverse events-1
Adverse events related to administration of reversal medications
Time frame: After operation within 24 hours
Adverse events-2
Adverse events related to residual paralysis
Time frame: After operation within 24 hours
Rescue medication neostigmine
A rescue dose of intravenous neostigmine at a dose of 0.03 mg/kg in the operating room after 15 minutes before discharge to recovery room.
Time frame: After operation within 120 minutes
Rescue medication sugammadex
A rescue dose of intravenous sugammadex at a dose of 1 mg/kg in the recovery room after 15 minutes before discharge to the ward from recovery room
Time frame: After operation within 120 minutes
Time frame-1
The time period between the last dose of intravenous rocuronium and administering a reversal agent
Time frame: After operation within 30 minutes
Time frame-2
The time period between administering a reversal agent to extubation
Time frame: After operation within 30 minutes
Time frame-3
The time period between administering a reversal agent to operating room discharge
Time frame: After operation within 60 minutes
Time frame-4
The time period between discharge from the operating room amd discharge from recovery room
Time frame: After operation within 120 minutes
Aldrete Score greater than nine in the recovery room
The criteria for patient discharge from the recovery room
Time frame: After operation within 120 minutes
Noninvasive mean arterial pressure
Mean arterial blood pressure measurements during operation and after operation
Time frame: During operation every 5 minutes and after operation in the recovery room every five minutes until discharge.
Heart rate
Heart rate measurements during operation and after operation
Time frame: During operation every 5 minutes and after operation in the recovery room every five minutes until discharge.
Peripheral oxygen saturation
Peripheral oxygen saturation during operation and after operation
Time frame: During operation every minute and after operation in the recovery room every minute until discharge.
No study locations are listed for this record.
Plan to share: Yes — We plan to share our data with individuals or organizations who reach us via phone, e-mail, or address.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: In a month after the release of the registration at https://register.clinicaltrials.gov.
Access criteria: The study is under peer review at a journal, and after its publication, we are planning to share our data individually by responding to each request.
Ran from May 2013 to primary completion in Oct 2016, 41 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Neostigmine · Sugammadex
Delayed Emergence from Anesthesia →
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital